donepezil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	946	120014-06-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aricept donepezil donepezil hydrochloride donepezil HCl donezpil hydrochloride donezpil donezpil HCl donepezilium oxalate trihydrate donepezilium oxalate donepezil oxalate E2020 E-2020	An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE. Molecular weight: 379.50 Formula: C24H29NO3 CLOGP: 4.60 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 38.77 ALOGS: -4.93 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

aricept
donepezil
donepezil hydrochloride
donepezil HCl
donezpil hydrochloride
donezpil
donezpil HCl
donepezilium oxalate trihydrate
donepezilium oxalate
donepezil oxalate
E2020
E-2020

An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.

Molecular weight: 379.50
Formula: C24H29NO3
CLOGP: 4.60
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 38.77
ALOGS: -4.93
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10.60 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Nov. 25, 1996	FDA	EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bradycardia	548.25	12.94	410	32886	70646	53245124
Fall	422.60	12.94	780	32516	357660	52958110
Dementia	312.15	12.94	169	33127	16581	53299189
Syncope	289.77	12.94	353	32943	111640	53204130
Electrocardiogram QT prolonged	281.91	12.94	253	33043	56150	53259620
Confusional state	237.13	12.94	430	32866	193791	53121979
Sinus bradycardia	232.87	12.94	133	33163	14468	53301302
Hallucination	207.07	12.94	209	33087	53629	53262141
Drug interaction	203.85	12.94	433	32863	218896	53096874
Torsade de pointes	187.61	12.94	111	33185	12894	53302876
Agitation	176.70	12.94	200	33096	58426	53257344
Cognitive disorder	165.19	12.94	170	33126	44608	53271162
Dementia Alzheimer's type	160.97	12.94	50	33246	1147	53314623
Delusion	156.42	12.94	96	33200	11913	53303857
Aggression	156.00	12.94	124	33172	23279	53292491
Abnormal behaviour	143.92	12.94	115	33181	21751	53294019
Delirium	139.80	12.94	150	33146	41279	53274491
Rheumatoid arthritis	133.41	12.94	19	33277	314512	53001258
Neuroleptic malignant syndrome	131.28	12.94	86	33210	11947	53303823
Parkinsonism	130.18	12.94	77	33219	8936	53306834
Drug ineffective	129.07	12.94	195	33101	817050	52498720
Pleurothotonus	118.29	12.94	41	33255	1338	53314432
Seizure	107.92	12.94	245	33051	129264	53186506
Arthralgia	105.41	12.94	73	33223	439710	52876060
Hallucination, visual	103.02	12.94	89	33207	18743	53297027
Somnolence	97.67	12.94	277	33019	167457	53148313
Cholinergic syndrome	90.74	12.94	25	33271	370	53315400
Sinus node dysfunction	89.65	12.94	47	33249	4314	53311456
Pain	88.24	12.94	145	33151	588253	52727517
Tremor	87.65	12.94	222	33074	125514	53190256
Loss of consciousness	86.31	12.94	208	33088	114004	53201766
Extrapyramidal disorder	85.40	12.94	67	33229	12335	53303435
Myoclonus	85.21	12.94	74	33222	15690	53300080
Alopecia	82.94	12.94	22	33274	234561	53081209
Altered state of consciousness	80.39	12.94	88	33208	24748	53291022
Electrocardiogram PR prolongation	80.00	12.94	26	33270	693	53315077
Femoral neck fracture	79.66	12.94	55	33241	8328	53307442
Muscle rigidity	77.75	12.94	60	33236	10781	53304989
Hypersensitivity	75.92	12.94	19	33277	210646	53105124
Decreased appetite	75.18	12.94	299	32997	214675	53101095
Depressed level of consciousness	74.58	12.94	127	33169	54301	53261469
Atrioventricular block first degree	74.45	12.94	48	33248	6487	53309283
Joint swelling	74.01	12.94	27	33269	234611	53081159
Dehydration	72.04	12.94	250	33046	168160	53147610
Hypothermia	72.01	12.94	62	33234	12994	53302776
Torticollis	71.21	12.94	31	33265	1879	53313891
Rash	70.54	12.94	106	33190	446085	52869685
Mental status changes	68.88	12.94	103	33193	39468	53276302
Immobile	66.11	12.94	41	33255	5179	53310591
Urinary retention	65.89	12.94	85	33211	28381	53287389
Mania	64.89	12.94	56	33240	11773	53303997
Treatment failure	64.24	12.94	4	33292	128399	53187371
Disorientation	63.64	12.94	99	33197	39260	53276510
Urinary incontinence	63.60	12.94	87	33209	30734	53285036
Hypokalaemia	62.68	12.94	166	33130	96351	53219419
Infusion related reaction	62.46	12.94	11	33285	155946	53159824
Systemic lupus erythematosus	59.60	12.94	5	33291	125409	53190361
Nightmare	59.37	12.94	64	33232	17687	53298083
Hypophagia	58.61	12.94	84	33212	30978	53284792
Sinusitis	57.34	12.94	17	33279	168547	53147223
Arthropathy	56.60	12.94	10	33286	141443	53174327
Lethargy	55.45	12.94	111	33185	53649	53262121
Urinary tract infection	54.42	12.94	294	33002	239609	53076161
Dyskinesia	52.76	12.94	81	33215	31752	53284018
Swelling	52.29	12.94	27	33269	191078	53124692
Pruritus	52.23	12.94	64	33232	293768	53022002
Sudden death	49.21	12.94	45	33251	10203	53305567
Drug hypersensitivity	49.03	12.94	56	33240	265186	53050584
Wandering pacemaker	48.49	12.94	8	33288	3	53315767
Unresponsive to stimuli	48.44	12.94	80	33216	33346	53282424
Gastrointestinal haemorrhage	46.02	12.94	132	33164	80198	53235572
Restlessness	45.89	12.94	71	33225	28016	53287754
Pain in extremity	45.66	12.94	67	33229	284983	53030787
Cerebral atrophy	45.60	12.94	32	33264	4972	53310798
Reduced facial expression	45.11	12.94	22	33274	1732	53314038
Glossodynia	45.01	12.94	5	33291	100286	53215484
Pemphigus	44.69	12.94	6	33290	104025	53211745
Psychomotor hyperactivity	43.99	12.94	42	33254	10054	53305716
Hypocapnia	43.33	12.94	14	33282	366	53315404
Circulatory collapse	42.23	12.94	61	33235	22653	53293117
Atrioventricular block complete	42.06	12.94	37	33259	7978	53307792
Generalised tonic-clonic seizure	41.90	12.94	69	33227	28689	53287081
Tardive dyskinesia	41.84	12.94	37	33259	8033	53307737
Drug intolerance	41.76	12.94	40	33256	205453	53110317
Encephalopathy	41.60	12.94	79	33217	36729	53279041
Anal incontinence	41.24	12.94	45	33251	12602	53303168
Apathy	40.89	12.94	37	33259	8275	53307495
Medication error	39.81	12.94	77	33219	36288	53279482
Cough	39.57	12.94	62	33234	256831	53058939
Hypersexuality	39.24	12.94	14	33282	498	53315272
Memory impairment	38.98	12.94	129	33167	84628	53231142
Sexually inappropriate behaviour	38.77	12.94	10	33286	113	53315657
Hip fracture	38.77	12.94	66	33230	28191	53287579
Febrile neutropenia	38.68	12.94	9	33287	104927	53210843
Headache	37.59	12.94	190	33106	536631	52779139
Lower respiratory tract infection	37.34	12.94	6	33290	90975	53224795
Off label use	37.26	12.94	160	33136	472052	52843718
Neuropsychiatric symptoms	36.39	12.94	14	33282	617	53315153
Pneumonia aspiration	35.57	12.94	71	33225	34230	53281540
Gait disturbance	35.52	12.94	194	33102	158648	53157122
Long QT syndrome	34.59	12.94	23	33273	3273	53312497
Miosis	34.12	12.94	31	33265	6971	53308799
Epilepsy	33.80	12.94	59	33237	25708	53290062
Psoriasis	33.04	12.94	7	33289	87082	53228688
Dementia with Lewy bodies	32.97	12.94	11	33285	319	53315451
Therapeutic product effect decreased	32.54	12.94	19	33277	125636	53190134
Listless	32.03	12.94	20	33276	2556	53313214
Weight increased	31.84	12.94	49	33247	204518	53111252
Atrioventricular block	31.67	12.94	30	33266	7110	53308660
Atrial tachycardia	31.64	12.94	19	33277	2265	53313505
Dyspnoea	31.30	12.94	226	33070	586006	52729764
Infection	31.10	12.94	37	33259	172168	53143602
Rhabdomyolysis	31.02	12.94	78	33218	43845	53271925
Lack of spontaneous speech	30.97	12.94	9	33287	163	53315607
Fatigue	30.73	12.94	300	32996	730206	52585564
Dizziness	30.68	12.94	361	32935	371898	52943872
Hyponatraemia	30.14	12.94	141	33155	108466	53207304
Parkinson's disease	30.05	12.94	16	33280	1515	53314255
Sinus arrest	29.93	12.94	17	33279	1827	53313943
Incontinence	29.56	12.94	35	33261	10708	53305062
Pericarditis	29.43	12.94	3	33293	64403	53251367
Product administration interrupted	29.43	12.94	13	33283	816	53314954
Paratonia	29.05	12.94	6	33290	22	53315748
Fluid intake reduced	28.88	12.94	21	33275	3448	53312322
Hypotension	28.80	12.94	263	33033	253813	53061957
Fracture	28.66	12.94	45	33251	17974	53297796
Stomatitis	28.14	12.94	13	33283	98145	53217625
Accidental overdose	27.94	12.94	49	33247	21430	53294340
Wrong patient received product	27.67	12.94	17	33279	2111	53313659
Dysarthria	27.56	12.94	71	33225	40497	53275273
Atrial fibrillation	27.43	12.94	140	33156	111512	53204258
Delusional disorder, persecutory type	27.22	12.94	8	33288	151	53315619
Nasopharyngitis	27.20	12.94	49	33247	192246	53123524
Hypernatraemia	26.56	12.94	27	33269	6970	53308800
Abdominal discomfort	26.46	12.94	62	33234	221000	53094770
Posture abnormal	26.17	12.94	17	33279	2326	53313444
Speech disorder	26.03	12.94	68	33228	39113	53276657
Overconfidence	25.52	12.94	4	33292	0	53315770
Cerebrovascular accident	25.23	12.94	131	33165	105043	53210727
Therapeutic product effect incomplete	25.03	12.94	13	33283	91771	53223999
Hyperhidrosis	24.93	12.94	123	33173	96670	53219100
Oropharyngeal pain	24.51	12.94	10	33286	81258	53234512
Grandiosity	24.28	12.94	8	33288	223	53315547
Pelvic fracture	24.15	12.94	34	33262	12330	53303440
Suspiciousness	24.10	12.94	9	33287	365	53315405
Cerebral haemorrhage	24.10	12.94	56	33240	29940	53285830
Product use issue	23.11	12.94	32	33264	139552	53176218
Colitis microscopic	22.71	12.94	25	33271	7069	53308701
Anger	22.63	12.94	33	33263	12357	53303413
Chorea	22.58	12.94	13	33283	1434	53314336
Ventricular tachycardia	22.43	12.94	40	33256	17722	53298048
Social avoidant behaviour	22.34	12.94	17	33279	2991	53312779
Bedridden	22.17	12.94	29	33267	9808	53305962
Drug level increased	22.05	12.94	43	33253	20378	53295392
Chest discomfort	21.93	12.94	18	33278	99677	53216093
Hepatic enzyme increased	21.84	12.94	28	33268	126167	53189603
Food refusal	21.67	12.94	8	33288	314	53315456
Incoherent	21.43	12.94	20	33276	4652	53311118
Salivary hypersecretion	21.42	12.94	24	33272	6919	53308851
Skull fracture	21.35	12.94	11	33285	974	53314796
Sedation	21.26	12.94	53	33243	29622	53286148
Hypertonia	21.20	12.94	20	33276	4717	53311053
Orthostatic hypotension	21.17	12.94	53	33243	29700	53286070
Impaired healing	20.88	12.94	7	33289	64198	53251572
Hypomania	20.68	12.94	20	33276	4862	53310908
Brain compression	20.47	12.94	8	33288	368	53315402
Psoriatic arthropathy	20.17	12.94	3	33293	48187	53267583
Psychotic disorder	20.11	12.94	46	33250	24339	53291431
Cerebral infarction	20.04	12.94	46	33250	24398	53291372
Drooling	20.04	12.94	17	33279	3491	53312279
Executive dysfunction	19.99	12.94	6	33290	122	53315648
Sinoatrial block	19.93	12.94	10	33286	837	53314933
Catatonia	19.91	12.94	18	33278	4022	53311748
Pyrexia	19.77	12.94	159	33137	403034	52912736
Urticaria	19.77	12.94	34	33262	135851	53179919
Vomiting	19.51	12.94	426	32870	496713	52819057
Inappropriate affect	19.47	12.94	10	33286	879	53314891
Hyponatraemic syndrome	19.36	12.94	9	33287	637	53315133
Adams-Stokes syndrome	19.35	12.94	5	33291	57	53315713
Peripheral swelling	19.33	12.94	65	33231	206043	53109727
Non-24-hour sleep-wake disorder	19.30	12.94	4	33292	15	53315755
Upper gastrointestinal haemorrhage	19.18	12.94	37	33259	17393	53298377
Normal pressure hydrocephalus	18.89	12.94	7	33289	278	53315492
Myalgia	18.88	12.94	34	33262	133457	53182313
Paranoia	18.82	12.94	29	33267	11395	53304375
Blood pressure orthostatic decreased	18.75	12.94	5	33291	65	53315705
Intentional product use issue	18.71	12.94	11	33285	72483	53243287
Antisocial behaviour	18.70	12.94	7	33289	286	53315484
Death	18.37	12.94	319	32977	356913	52958857
Injection site erythema	18.19	12.94	13	33283	77236	53238534
Muscle contracture	18.12	12.94	11	33285	1337	53314433
Foreign body	17.97	12.94	13	33283	2118	53313652
Anaphylactic reaction	17.87	12.94	7	33289	58319	53257451
Emotional poverty	17.87	12.94	7	33289	324	53315446
Herbal interaction	17.84	12.94	5	33291	79	53315691
Injection site pain	17.78	12.94	27	33269	113364	53202406
Obsessive thoughts	17.63	12.94	8	33288	535	53315235
Abnormal dreams	17.59	12.94	27	33269	10574	53305196
Prescription drug used without a prescription	17.58	12.94	12	33284	1782	53313988
Wound	17.24	12.94	19	33277	91538	53224232
Affect lability	17.16	12.94	25	33271	9350	53306420
Dyspepsia	17.07	12.94	14	33282	77586	53238184
Aphasia	17.06	12.94	50	33246	30728	53285042
Asthma	17.04	12.94	26	33270	108946	53206824
Leukaemoid reaction	17.02	12.94	6	33290	206	53315564
Pressure of speech	16.86	12.94	8	33288	593	53315177
Liver function test abnormal	16.85	12.94	67	33229	48004	53267766
Rash papulosquamous	16.79	12.94	5	33291	99	53315671
Anorgasmia	16.76	12.94	8	33288	601	53315169
Discomfort	16.71	12.94	21	33275	95451	53220319
Paraesthesia	16.70	12.94	34	33262	127481	53188289
Hypoglycaemia	16.64	12.94	77	33219	58936	53256834
Duodenal ulcer haemorrhage	16.31	12.94	13	33283	2447	53313323
Communication disorder	16.30	12.94	13	33283	2448	53313322
Disease progression	16.24	12.94	24	33272	101896	53213874
Intercepted product dispensing error	16.16	12.94	5	33291	113	53315657
Hypoaesthesia	16.14	12.94	37	33259	132958	53182812
Injection site reaction	15.91	12.94	6	33290	51160	53264610
Fibromyalgia	15.80	12.94	4	33292	44071	53271699
Neutropenia	15.75	12.94	49	33247	159136	53156634
Irritable bowel syndrome	15.57	12.94	4	33292	43628	53272142
Product use in unapproved indication	15.52	12.94	29	33267	112260	53203510
Product dispensing error	15.50	12.94	25	33271	10215	53305555
Arthritis	15.49	12.94	19	33277	87279	53228491
Drop attacks	15.17	12.94	8	33288	743	53315027
Haematoma	15.09	12.94	51	33245	33793	53281977
Erythema	15.06	12.94	49	33247	156920	53158850
Injection site swelling	15.03	12.94	4	33292	42624	53273146
Gastric ulcer	14.95	12.94	40	33256	23329	53292441
Dysphagia	14.93	12.94	97	33199	84300	53231470
Delusion of grandeur	14.79	12.94	5	33291	151	53315619
Gastric ulcer haemorrhage	14.72	12.94	17	33279	5065	53310705
Libido increased	14.69	12.94	9	33287	1112	53314658
Language disorder	14.63	12.94	11	33285	1900	53313870
Pemphigoid	14.53	12.94	19	33277	6425	53309345
Cholesteatoma	14.52	12.94	5	33291	160	53315610
Heart rate increased	14.51	12.94	18	33278	82297	53233473
Impaired self-care	14.51	12.94	11	33285	1924	53313846
Blood glucose fluctuation	14.50	12.94	16	33280	4535	53311235
Malignant neoplasm progression	14.43	12.94	14	33282	71527	53244243
Amnesia	14.21	12.94	61	33235	45227	53270543
Crying	14.14	12.94	38	33258	22224	53293546
Neuropathy peripheral	13.95	12.94	27	33269	103160	53212610
Opisthotonus	13.95	12.94	6	33290	353	53315417
Nasal congestion	13.87	12.94	8	33288	53279	53262491
Progressive supranuclear palsy	13.74	12.94	4	33292	73	53315697
Acute abdomen	13.72	12.94	10	33286	1648	53314122
Subdural haematoma	13.61	12.94	28	33268	13785	53301985
Muscle twitching	13.56	12.94	31	33265	16395	53299375
Visuospatial deficit	13.46	12.94	3	33293	17	53315753
Thalamus haemorrhage	13.46	12.94	7	33289	632	53315138
Hypoglycaemic coma	13.41	12.94	12	33284	2646	53313124
Product blister packaging issue	13.39	12.94	5	33291	203	53315567
Haematemesis	13.32	12.94	46	33250	30811	53284959
Bundle branch block left	13.27	12.94	19	33277	6994	53308776
Gait inability	13.11	12.94	53	33243	38258	53277512
Apraxia	13.10	12.94	10	33286	1768	53314002
Inflammation	12.96	12.94	10	33286	57126	53258644

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	379.43	14.39	313	23786	52306	32437121
Dementia	369.74	14.39	186	23913	13200	32476227
Fall	331.85	14.39	551	23548	195650	32293777
Bradycardia	311.46	14.39	321	23778	71241	32418186
Confusional state	271.67	14.39	424	23675	142691	32346736
Agitation	185.19	14.39	220	23879	57016	32432411
Delusion	184.10	14.39	117	23982	12991	32476436
Delirium	146.87	14.39	172	23927	43874	32445553
Aggression	136.65	14.39	157	23942	39232	32450195
Pleurothotonus	129.10	14.39	43	24056	1038	32488389
Abnormal behaviour	128.20	14.39	126	23973	26340	32463087
Cognitive disorder	126.78	14.39	124	23975	25770	32463657
Cholinergic syndrome	100.93	14.39	30	24069	492	32488935
Depressed level of consciousness	94.34	14.39	133	23966	40714	32448713
Hallucination, visual	93.12	14.39	87	24012	17072	32472355
Somnolence	85.36	14.39	217	23882	103580	32385847
Mania	83.58	14.39	64	24035	9568	32479859
Neuroleptic malignant syndrome	82.30	14.39	82	24017	17413	32472014
Syncope	78.90	14.39	193	23906	89931	32399496
Urinary incontinence	74.19	14.39	79	24020	18128	32471299
Sinus node dysfunction	69.28	14.39	41	24058	4003	32485424
Sinus bradycardia	69.04	14.39	65	24034	12873	32476554
Dementia Alzheimer's type	66.61	14.39	21	24078	423	32489004
Gait disturbance	61.83	14.39	164	23935	80244	32409183
Memory impairment	61.75	14.39	109	23990	40370	32449057
Febrile neutropenia	61.52	14.39	8	24091	119558	32369869
Balance disorder	59.86	14.39	106	23993	39353	32450074
Nightmare	58.78	14.39	60	24039	13106	32476321
Blood cholinesterase decreased	55.28	14.39	14	24085	121	32489306
Serotonin syndrome	49.77	14.39	66	24033	19051	32470376
Pneumonia aspiration	45.81	14.39	97	24002	41059	32448368
Parkinsonism	44.81	14.39	41	24058	7828	32481599
Neutropenia	44.55	14.39	25	24074	142150	32347277
Unresponsive to stimuli	44.25	14.39	76	24023	27533	32461894
Tremor	43.64	14.39	146	23953	81131	32408296
Prescribed underdose	41.48	14.39	41	24058	8618	32480809
Poriomania	41.05	14.39	11	24088	121	32489306
Extrapyramidal disorder	40.50	14.39	47	24052	11848	32477579
Loss of consciousness	40.42	14.39	144	23955	82563	32406864
Orthostatic hypotension	40.31	14.39	70	24029	25580	32463847
Death	39.67	14.39	445	23654	382072	32107355
Libido increased	39.37	14.39	17	24082	848	32488579
Hyperhidrosis	39.23	14.39	129	23970	71039	32418388
Myoclonus	38.84	14.39	51	24048	14578	32474849
Disorientation	37.45	14.39	79	24020	33346	32456081
Anal incontinence	35.96	14.39	35	24064	7219	32482208
Dyskinesia	35.26	14.39	63	24036	23540	32465887
Arthralgia	35.06	14.39	35	24064	148413	32341014
Automatism	34.18	14.39	9	24090	92	32489335
Jealous delusion	33.08	14.39	11	24088	264	32489163
Restlessness	32.88	14.39	63	24036	24818	32464609
Paranoia	32.38	14.39	40	24059	10759	32478668
Mental status changes	32.32	14.39	81	24018	38256	32451171
Hypersomnia	32.22	14.39	42	24057	11919	32477508
Rhabdomyolysis	31.90	14.39	116	23983	67149	32422278
Somatic delusion	31.59	14.39	9	24090	126	32489301
Dizziness	31.58	14.39	264	23835	209354	32280073
Lethargy	31.56	14.39	84	24015	41144	32448283
Product prescribing issue	31.45	14.39	16	24083	1159	32488268
Blood glucose fluctuation	31.23	14.39	25	24074	3984	32485443
Salivary hypersecretion	31.02	14.39	34	24065	8054	32481373
Intestinal haemorrhage	30.51	14.39	23	24076	3356	32486071
Dyspnoea	29.66	14.39	153	23946	361892	32127535
Bradyarrhythmia	29.66	14.39	19	24080	2135	32487292
Parkinson's disease	28.26	14.39	17	24082	1709	32487718
Abdominal pain	28.18	14.39	42	24057	149487	32339940
Sexually inappropriate behaviour	27.46	14.39	11	24088	453	32488974
Nonspecific reaction	26.80	14.39	15	24084	1317	32488110
Drooling	26.62	14.39	21	24078	3276	32486151
Electrocardiogram QT prolonged	26.61	14.39	77	24022	39564	32449863
Hypothermia	26.47	14.39	35	24064	10068	32479359
Dementia with Lewy bodies	26.45	14.39	12	24087	674	32488753
Psychomotor hyperactivity	26.33	14.39	33	24066	9006	32480421
Flight of ideas	26.19	14.39	10	24089	362	32489065
Dysstasia	25.89	14.39	37	24062	11449	32477978
Thrombocytopenia	25.73	14.39	44	24055	148255	32341172
Miosis	25.71	14.39	32	24067	8672	32480755
Drug abuse	25.27	14.39	14	24085	80229	32409198
Seizure	25.18	14.39	147	23952	103707	32385720
Muscle rigidity	25.17	14.39	36	24063	11150	32478277
Hip fracture	24.95	14.39	37	24062	11838	32477589
Drug interaction	24.90	14.39	259	23840	217926	32271501
Neuropathy peripheral	24.87	14.39	13	24086	76969	32412458
Gastrointestinal haemorrhage	24.41	14.39	128	23971	86754	32402673
Muscle contractions involuntary	24.08	14.39	16	24083	1912	32487515
Altered state of consciousness	23.49	14.39	51	24048	21946	32467481
Atrioventricular block complete	23.46	14.39	31	24068	8913	32480514
Contusion	23.43	14.39	66	24033	33402	32456025
Pain	23.22	14.39	67	24032	187489	32301938
Gait inability	23.17	14.39	48	24051	19999	32469428
Dehydration	23.01	14.39	169	23930	128789	32360638
Cerebral atrophy	22.73	14.39	22	24077	4505	32484922
Neutrophil count decreased	22.29	14.39	4	24095	47135	32442292
Irritability	21.74	14.39	53	24046	24601	32464826
Daydreaming	21.72	14.39	10	24089	581	32488846
Inappropriate antidiuretic hormone secretion	21.72	14.39	35	24064	12028	32477399
Skin swelling	21.67	14.39	12	24087	1032	32488395
Atrioventricular block first degree	21.57	14.39	24	24075	5779	32483648
Hangover	21.10	14.39	12	24087	1087	32488340
Femoral neck fracture	21.07	14.39	18	24081	3138	32486289
Cold sweat	20.91	14.39	31	24068	9915	32479512
Pruritus	20.69	14.39	40	24059	128662	32360765
Blood glucose abnormal	20.58	14.39	23	24076	5565	32483862
Gastrointestinal ulcer	20.37	14.39	14	24085	1769	32487658
Septic shock	20.36	14.39	13	24086	68976	32420451
Malignant neoplasm progression	20.30	14.39	17	24082	78479	32410948
Subdural haematoma	19.88	14.39	45	24054	19908	32469519
Executive dysfunction	19.86	14.39	7	24092	201	32489226
Multiple organ dysfunction syndrome	19.50	14.39	14	24085	69840	32419587
Intention tremor	19.30	14.39	8	24091	360	32489067
Defect conduction intraventricular	19.27	14.39	7	24092	220	32489207
Paraesthesia	18.97	14.39	10	24089	58934	32430493
Speech disorder	18.59	14.39	52	24047	26201	32463226
Urinary tract infection	18.53	14.39	112	23987	79959	32409468
Gastroenteritis pseudomonas	18.41	14.39	4	24095	16	32489411
Duodenal ulcer	18.37	14.39	30	24069	10425	32479002
Decreased appetite	18.36	14.39	191	23908	160622	32328805
Hiccups	18.21	14.39	29	24070	9866	32479561
Posture abnormal	17.77	14.39	14	24085	2179	32487248
Potentiating drug interaction	17.40	14.39	20	24079	4988	32484439
Behaviour disorder	17.06	14.39	17	24082	3607	32485820
Condition aggravated	16.89	14.39	183	23916	155478	32333949
Leukopenia	16.84	14.39	12	24087	60110	32429317
Rheumatoid arthritis	16.80	14.39	6	24093	44538	32444889
Atrioventricular block	16.29	14.39	24	24075	7631	32481796
Foaming at mouth	16.02	14.39	9	24090	796	32488631
Underdose	15.94	14.39	32	24067	13037	32476390
Multiple drug therapy	15.88	14.39	7	24092	367	32489060
Tardive dyskinesia	15.80	14.39	20	24079	5511	32483916
Impulsive behaviour	15.68	14.39	13	24086	2176	32487251
Incontinence	15.53	14.39	20	24079	5606	32483821
Drug hypersensitivity	15.44	14.39	19	24080	73381	32416046
Urticaria	15.30	14.39	13	24086	59601	32429826
Post-traumatic stress disorder	15.28	14.39	12	24087	1859	32487568
Pyrexia	15.12	14.39	158	23941	319810	32169617
Loss of personal independence in daily activities	15.09	14.39	49	24050	26784	32462643
Hypernatraemia	14.97	14.39	24	24075	8209	32481218
Hypomania	14.60	14.39	13	24086	2396	32487031
Musculoskeletal pain	14.46	14.39	3	24096	31894	32457533
Frontotemporal dementia	14.39	14.39	6	24093	274	32489153

Pharmacologic Action:

Source	Code	Description
ATC	N06DA02	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
ATC	N06DA52	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
ATC	N06DA53	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
FDA MoA	N0000000177	Cholinesterase Inhibitors
CHEBI has role	CHEBI:38462	acetylcholine esterase inhibitor
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D002800	Cholinesterase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018697	Nootropic Agents
FDA EPC	N0000175723	Cholinesterase Inhibitor
CHEBI has role	CHEBI:37733	BChE inhibitor
CHEBI has role	CHEBI:66980	nootropics

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Alzheimer's disease	indication	26929004	DOID:10652
Moderate to Severe Alzheimer's Type Dementia	indication
Diffuse Lewy body disease	off-label use	80098002
Sick sinus syndrome	contraindication	36083008	DOID:13884
Gastrointestinal ulcer	contraindication	40845000
Sinus bradycardia	contraindication	49710005
Gastrointestinal hemorrhage	contraindication	74474003
Epilepsy	contraindication	84757009	DOID:1826
Asthma	contraindication	195967001	DOID:2841
Atrioventricular block	contraindication	233917008	DOID:0050820
Bladder outflow obstruction	contraindication	236645006
NSAID-Induced Gastric Ulcer	contraindication
Chronic Obstructive Pulmonary Disease with Bronchospasms	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.4	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG;14MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ALLERGAN	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ALLERGAN	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN	INHIBITOR	Ki	7.80	WOMBAT-PK	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.70	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.46	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.05	WOMBAT-PK
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN		IC50	4.82	CHEMBL
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		Ki	4.90	CHEMBL
Histamine H3 receptor	GPCR	Q9Y5N1	HRH3_HUMAN		IC50	6.46	CHEMBL
Beta-secretase 1	Enzyme	P56817	BACE1_HUMAN		IC50	5.49	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.84	CHEMBL
Acetylcholinesterase	Enzyme		ACES_TORCA		IC50	8.24	CHEMBL
Acetylcholinesterase	Enzyme		ACES_MOUSE		IC50	8.24	CHEMBL
Butyrylcholinesterase; Protein Bche	Enzyme		Q9JKC1_RAT		IC50	5.56	CHEMBL
Acetylcholinesterase	Enzyme		ACES_RAT		IC50	8.77	CHEMBL
Acetylcholinesterase	Enzyme		ACES_ELEEL		Ki	7.25	CHEMBL
Acetylcholinesterase	Enzyme		ACES_BOVIN		Ki	8.54	CHEMBL
Choline O-acetyltransferase	Enzyme		CLAT_RAT		IC50	8.28	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		IC50	4.82	CHEMBL
Cholinesterase	Enzyme		CHLE_MOUSE		IC50	5.15	CHEMBL
Butyrylcholinesterase	Enzyme		Q9N1N9_HORSE		Ki	6.19	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane other		SGMR1_CAVPO		Ki	7.84	CHEMBL
Cholinesterase	Enzyme		CHLE_HORSE		IC50	6.08	CHEMBL

External reference:

ID	Source
D00670	KEGG_DRUG
120011-70-3	SECONDARY_CAS_RN
4021006	VANDF
4024045	VANDF
C0527316	UMLSCUI
CHEBI:53289	CHEBI
E20	PDB_CHEM_ID
CHEMBL502	ChEMBL_ID
CHEMBL1678	ChEMBL_ID
DB00843	DRUGBANK_ID
D000077265	MESH_DESCRIPTOR_UI
3152	PUBCHEM_CID
6599	IUPHAR_LIGAND_ID
7517	INN_ID
8SSC91326P	UNII
135446	RXNORM
15004	MMSL
178540	MMSL
4631	MMSL
6432	MMSL
d04099	MMSL
006295	NDDF
006296	NDDF
108497001	SNOMEDCT_US
386855006	SNOMEDCT_US
386856007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9747	TABLET, FILM COATED	5 mg	ORAL	ANDA	24 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9748	TABLET, FILM COATED	10 mg	ORAL	ANDA	24 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1207	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1214	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1221	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1228	CAPSULE	10 mg	ORAL	NDA	31 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7951	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7952	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8313	TABLET, FILM COATED	10 mg	ORAL	ANDA	19 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5276	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	26 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5277	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	26 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6477	TABLET, FILM COATED	5 mg	ORAL	ANDA	24 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6478	TABLET, FILM COATED	10 mg	ORAL	ANDA	24 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-102	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-103	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	Human Prescription Drug Label	1	16571-778	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections
Donepezil Hydrochloride	Human Prescription Drug Label	1	16571-779	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
DONEPEZIL HYDROCHLORIDE	Human Prescription Drug Label	1	24724-028	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
DONEPEZIL HYDROCHLORIDE	Human Prescription Drug Label	1	24724-029	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24979-004	TABLET, FILM COATED	23 mg	ORAL	ANDA	16 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-248	TABLET, FILM COATED	5 mg	ORAL	ANDA	23 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-249	TABLET, FILM COATED	10 mg	ORAL	ANDA	23 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-250	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	23 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-251	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	23 sections
Donepezil hydrochloride	Human Prescription Drug Label	1	31722-139	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Donepezil hydrochloride	Human Prescription Drug Label	1	31722-140	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Donepezil	Human Prescription Drug Label	1	31722-737	TABLET	5 mg	ORAL	ANDA	19 sections
Donepezil	Human Prescription Drug Label	1	31722-738	TABLET	10 mg	ORAL	ANDA	19 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-817	TABLET, FILM COATED	10 mg	ORAL	ANDA	19 sections
Donepezil Hydrochloride	Human Prescription Drug Label	1	33342-027	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections